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Abstract
Long-term delivery of potent broadly-neutralizing antibodies is a promising approach for the
prevention of HIV-1 infection. We used AAV vector intramuscularly to deliver anti-SIV mono-
clonal antibodies (mAbs) in IgG1 form to rhesus monkeys. Persisting levels of delivered
mAb as high as 270 μg/ml were achieved. However, host antibody responses to the deliv-
ered antibody were observed in 9 of the 12 monkeys and these appeared to limit the con-
centration of delivered antibody that could be achieved. This is reflected in the wide range
of delivered mAb concentrations that were achieved: 1–270 μg/ml. Following repeated,
marginal dose, intravenous challenge with the difficult-to-neutralize SIVmac239, the six
monkeys in the AAV-5L7 IgG1 mAb group showed clear protective effects despite the
absence of detectable neutralizing activity against the challenge virus. The protective
effects included: lowering of viral load at peak height; lowering of viral load at set point;
delay in the time to peak viral load from the time of the infectious virus exposure. All of these
effects were statistically significant. In addition, the monkey with the highest level of deliv-
ered 5L7 mAb completely resisted six successive SIVmac239 i.v. challenges, including a
final challenge with a dose of 10 i.v. infectious units. Our results demonstrate the continued
promise of this approach for the prevention of HIV-1 infection in people. However, the prob-
lem of anti-antibody responses will need to be understood and overcome for the promise of
this approach to be effectively realized.
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Author Summary
AAV-mediated antibody delivery represents a promising alternative to classical vaccine
approaches for the prevention of HIV/AIDS in humans. We used recombinant adeno-
associated viral vectors (rAAV) as gene carrier to deliver anti-SIV (simian immunodefi-
ciency virus) antibodies to monkeys. This non-classical immunization approach is inde-
pendent of the host immune system and the AAV-transferred gene into muscle cells
produces antibodies with known specificities. Our goal was to determine what serum levels
of delivered antibodies can be achieved by using two different vector strategies, whether
the delivered antibodies provoke an immune response, and to what degree the delivered
non-neutralizing antibodies have the ability to protect against SIV virus challenge. This
approach allowed for sustained levels of delivered antibodies in serum and exhibited sig-
nificant protective effects against highly pathogenic SIVmac239 challenge. However,
immune responses limited the concentration of circulating antibodies that could be
achieved. This problem will need to be understood and overcome for the promise of this
approach to be effectively realized.
Introduction
There are good reasons for believing that development of an effective preventive vaccine
against HIV-1 is going to be a very difficult task. HIV-1 has evolved a variety of immune eva-
sion strategies that allow continuous virus replication in the face of apparently strong host
immune responses, both cellular and humoral [1,2]. For a vaccine to be effective it will likely
need to either completely block the initial infection or to provide immune responses that are
more effective than those resulting from infection.
One promising, creative approach is to use adeno-associated virus (AAV) vector to deliver
antibodies with potent and broadly neutralizing activity [3–7]. This method is an alternative to
classical immunization and independent of the host immune system. Proteins delivered by
AAV vector can persist at stable levels for years [8,9], and AAV vectors have proven to be safe
and effective in human gene therapy trials against a number of diseases [10–13]. More than a
dozen potent broadly neutralizing anti-HIV-1 monoclonal antibodies have already been char-
acterized; they are human-derived, they can effectively neutralize more than 90% of circulating
HIV-1 strains, and they represent a range of different specificities [14–21].
In a previous pioneering study performed in monkeys, anti-SIV immunoadhesins (anti-
body-like molecules) were delivered by AAV vector and a reasonable percentage of the mon-
keys exhibited apparent sterilizing immunity against intravenous (i.v.) challenge by
SIVmac316 [4]. However, SIVmac316 is an easy-to-neutralize SIV strain, one third of the
immunized monkeys developed antibody responses (anti-anti) to the delivered immunoadhe-
sin, and monkeys with anti-anti responses were not protected against the challenge. It was not
clear from that initial study to what extent anti-anti responses may have resulted from delivery
of immunoadhesins, which do not represent an authentic IgG structure. We decided to build
upon these studies by using AAV to deliver authentic IgG and to examine protection against
the difficult-to-neutralize strain SIVmac239. At the time these studies were initiated, there
were no monoclonal antibodies available that could neutralize SIVmac239. We thus converted
the previously reported immunoadhesins 4L6 and 5L7 [4] into authentic IgG versions. These
anti-SIV mAbs in IgG1 form contain only authentic rhesus IgG sequences. In this study we
describe the AAV-mediated delivery of these full-length immunoglobulins to rhesus macaques
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and the protective effects of the non-neutralizing antibody 5L7 IgG1 against SIVmac239
challenge.
Results
AAV-mediated delivery of mAbs
Two fundamentally different types of AAV systems are available for vector-mediated delivery:
single-stranded (ssAAV) vs. self-complementary (scAAV) [22]. scAAV has been reported to
achieve considerably higher levels of transgene expression [23,24] but suffers from the draw-
back of not being able to accommodate sufficient genetic information for the expression of
both heavy (H) and light (L) chains needed for authentic IgG [25]. We thus developed two
strategies for AAV-mediated synthesis of authentic IgG for comparison purposes: ssAAV for
the synthesis of matched H and L chains from a single vector vs. scAAV for the synthesis of H
and L chains from separate vectors, an approach that we will call the two vector approach. The
logic behind the two vector approach is that such a high quantity of AAV vector particles is
inoculated into a highly localized area of muscle that it seems likely that many, perhaps even a
majority, of cells will take up multiple AAV particles. We sought to deliver authentic IgG ver-
sions of the previously described monoclonal Fabs 346-16h and 347-23h [26] in order to allow
comparison to the results of Johnson et al. that utilized immunoadhesins with these binding
specificities (called 4L6 and 5L7, respectively) [4]. Since SIVmac239 was planned for challenge,
this also allowed investigation of protective effects in the absence of virus-neutralizing activity.
We employed IgG1 sequences in order to maximize antibody-dependent cellular cytotoxicity
(ADCC) activity and other effector functions. We used AAV serotype 1 for intramuscular
expression. The constructs shown in (S1 Fig) were demonstrated to express authentic rhesus
IgG with expected properties prior to the initiation of monkey experiments.
In our first monkey study, three AAV1-negative monkeys were inoculated intramuscularly
with 1.6 x 1013 ssAAV vector particles expressing both heavy and light chains of the authentic
rhesus monkey IgG1 monoclonal antibody 5L7 (ssAAV-5L7 IgG1). On the same date, three
AAV1-negative monkeys were inoculated with 0.8 x 1013 scAAV vector particles expressing
5L7 IgG1 heavy chain and 0.8 x 1013 scAAV vector particles expressing 5L7 kappa light chain
(scAAV-5L7 IgG1 H + scAAV-5L7 kappa L). The levels of delivered 5L7 mAb in plasma were
measured by a gp140 ELISA and purified mAb as standard. Considerable monkey-to-monkey
variation was observed in the levels of 5L7 IgG1 that were achieved (Fig 1A). However, the lev-
els in each individual monkey remained stable over the course of months leading up to the
time of challenge. There were no clear differences in the persisting levels of 5L7 IgG1 mAb
associated with the one vector vs. two vector delivery systems. While monkey 153–10 in the
one vector group achieved persisting levels of 5L7 IgG1 mAb of only 1–5 μg/ml, monkey 84–
05, also in the one vector group, achieved remarkable levels of approximately 270 μg/ml that
have persisted now for more than two years. Three of the six monkeys in this first study had
clear antibody responses to the delivered 5L7 IgG1 mAb (Fig 1C and S2 Fig). Monkey 153–10
with the lowest level of persisting 5L7 mAb had the strongest anti-anti response, while monkey
84–05 with the highest level of persisting 5L7 mAb had no detectable anti-anti response. The
other two monkeys without detectable anti-anti responses (111–09 and 154–10) were in the
two vector scAAV group.
In our second monkey study, we used the one vector ssAAV approach to deliver the 4L6
mAb in IgG1 form to six AAV1-negative monkeys. In this experiment, the levels of delivered
4L6 mAb peaked 3–4 weeks after administration and then fell precipitously (Fig 1B). All six of
the recombinant AAV-4L6 recipients had antibody responses to the delivered 4L6 mAb whose
appearance coincided with the precipitous decline in 4L6 mAb levels (Fig 1D and S3 Fig). The
Antibody Responses to AAV-Delivered Antibodies
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Fig 1. Serum concentration of the IgG1mAbs 4L6 and 5L7, and emerging anti-mAb responses following recombinant AAV administration. Levels
of produced antibodies were measured in sera from immunized animals over time by a gp140 capture ELISA. SIV challenge is indicated by arrows. (A)
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anti-anti responses in the 5L7 IgG1 recipients (Fig 1C) were largely specific for 5L7 while the
anti-anti responses in the 4L6 IgG1 recipients (Fig 1D) were largely specific for 4L6; since the
5L7 and 4L6 IgG1s have the exact same constant regions, these results indicate that the
responses were mostly directed to the variable domains (Fig 1E and 1F). By week 14, the time
of SIV challenge, the levels of 4L6 mAb in two of the recipients (279–10 and 283–10) had
dropped to undetectable levels, while the levels in the other four monkeys had dropped to
1–38 μg/ml (Fig 1B).
SIV challenge of monkeys
Six appropriately-matched control rhesus monkeys were enrolled in the challenge phase (S1
Table). Repeated, marginal dose, intravenous challenges were simultaneously initiated to con-
trol monkeys, to the 5L7 mAb group 44 weeks after their administration of recombinant AAV-
5L7 IgG1, and to the 4L6 mAb group 14 weeks after their administration of recombinant
AAV-4L6 IgG1. Administrations were performed every three weeks such that administrations
were stopped when a monkey became infected from the previous exposure. A PBMC-grown
stock of cloned SIVmac239 was used, one that has been carefully titered previously by the i.v.
route in monkeys and has been used extensively by numerous investigators for controlled dose
challenges [27–35]. One i.v. animal infectious dose was used through the first four administra-
tions, 2 i.v. infectious doses for the fifth administration, and 10 i.v. infectious doses for the
sixth administration.
Only one monkey of the 18 resisted all six challenges: monkey 84–05 with the highest levels
of delivered mAb (averaging approximately 270 μg/ml of the 5L7 mAb through all of the chal-
lenges) (Fig 2A). Dozens of control monkeys have been challenged with the 10x dose of this
exact same stock in numerous previous studies and not a single monkey has been refractory to
infection [27–35]. The absence of anti-gp41 antibody responses in 84–05 even following the
10x challenge is consistent with the apparent sterilizing immunity in this animal (S4 Fig). Oth-
erwise, no significant difference in the acquisition of SIV infection was observed among the
test vs. control monkeys (Fig 2A).
Given that levels of delivered 4L6 IgG1 mAb were driven to low or undetectable levels by
the time of first challenge in most monkeys in this group, it is not surprising that plasma virion
SIV RNA levels in the 4L6 mAb group as a function of weeks following the infectious exposure
were not significantly different from control monkeys, neither at peak viremia nor during
chronic phase infection (Fig 2B and 2C; Fig 2E). However, SIV plasma RNA loads in the 5L7
mAb group were significantly lower than those in the control group both at peak viremia (Δ of
0.67 logs) and during chronic phase infection (Δ of 2.06 logs) (Fig 2B and 2C; Fig 2F). The dif-
ferences were significant whether or not the undetectable viral loads of monkey 84–05 were
included in the analyses. The viral loads in the 5L7 mAb group at set point were also signifi-
cantly lower than those in the 4L6 mAb group (Fig 2C). The duration in weeks from the time
of the infectious exposure to peak plasma viral loads was also significantly different between
the 5L7 mAb group and the control group (Fig 2D). While there is a suggestion that viral loads
Animals that received rAAV-5L7 IgG1. 84–05, 153–10 and 157–10 were given one ssAAV vector expressing both heavy and light chain of the antibody 5L7
IgG1. 111–09, 120–09 and 154–10 were given an equal mixture of two scAAV vectors expressing either heavy chain or light chain of the antibody 5L7 IgG1.
(B) Animals that received rAAV-4L6 IgG1. All six animals were given one ssAAV vector expressing both heavy and light chain of the antibody 4L6 IgG1. (C
andD) Antibody responses to 5L7 IgG1 and 4L6 IgG1, respectively, following recombinant AAV administration. Humoral immune responses were measured
in sera from immunized animals over time by ELISA. The reactivity of serum was tested against homologous purified protein using a conjugated anti-lambda
secondary antibody for detection since both 5L7 IgG1 and 4L6 IgG1 bear a kappa light chain. (E) Reactivity of sera from 5L7 IgG1 recipients to purified mAbs
and immunoadhesins at week 10 after AAV administration. (F) Reactivity of sera from 4L6 IgG1 animals to purified mAbs and immunoadhesins at week 6
after AAV administration.
doi:10.1371/journal.ppat.1005090.g001
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at peak height were inversely correlated with the levels of delivered 5L7 mAb, this correlation
did not reach statistical significance (S5 Fig). There was no obvious association of measured
4L6 IgG1 levels in serum at the time of infectious exposure with the time to peak viremia (S6
Fig).
Effector functions
Both the 5L7 and the 4L6 mAb IgG1s lack detectable neutralizing activity against the challenge
strain SIVmac239 (Fig 3A). In fact, even at 1 mg/ml of the 5L7 mAb IgG1, 50% neutraliza-
tion of SIVmac239 was not achieved (Fig 3B). However, both the 5L7 and 4L6 mAbs had
neutralizing activity against the neutralization-sensitive derivative of SIVmac239 called SIV-
mac316 (Fig 3C). The half-maximal inhibitory concentrations (IC50s) against SIVmac316
were 0.0015 μg/ml (4L6 IgG1) and 0.003 μg/ml (5L7 IgG1), which are consistent with previ-
ously described IC50s for Fab molecule and immunoadhesin versions of these mAbs [4,26].
The concentrations of mAb in sera shown in (Fig 1A) were measured biochemically with a
gp140 ELISA using varying amounts of purified mAb produced by transfection of 293T cells in
culture as standards. In order to validate the biochemically measured mAb concentrations and
to confirm the expected neutralizing activity in serum against SIVmac316, serum samples were
diluted to contain a starting concentration of 4 μg/ml 5L7 mAb based on the biochemically-
measured concentration and neutralizing activity against SIVmac316 was measured (Fig 3D).
The neutralizing activity in serum agreed spot-on with the biochemically-measured concentra-
tion of the 5L7 mAb for all six samples. As expected, sera from 84–05 lacked detectable neutral-
izing activity against SIVmac239 (Fig 3E). HEK 293T-expressed purified immunoadhesins and
mAbs showed equivalent binding to SIVmac239 gp140 as determined by ELISA (Fig 3F).
With this information in hand, we proceeded to measure ADCC activity in pre-challenge
serum samples relative to the biochemically measured 5L7 mAb concentrations in them. We
used an assay that measures natural killer (NK) cell-mediated ADCC activity of mAb or serum
independent of neutralization or complement activity [36]. The assay uses a NK cell line that
expresses macaque CD16 as effector cell and a CD4+ T cell line that expresses luciferase upon
SIV infection as target. 5L7 IgG1 purified from 293T transfection was diluted to match the
starting concentration of 5L7 IgG1 in the serum sample to which it was being compared.
Serum from 84–05 was unusual in that it had markedly higher ADCC activity than the equiva-
lent concentration of purified 5L7 IgG1 (Fig 4A and 4B). Pre-AAV serum from 84–05 con-
tained no measurable activity capable of enhancing the ADCC activity of purified 5L7 IgG1 (S7
Fig). Four of the five remaining animals in the group had ADCC activity in their serum sam-
ples comparable to that of purified 5L7 IgG1 at equivalent concentrations (Fig 4A and 4B; S8
Fig). Serum from monkey 111–09, the monkey with the lowest post-challenge viremia, also
had somewhat higher ADCC activity compared to purified 5L7 IgG1 at equivalent concentra-
tions (S8 Fig).
Fig 2. Repeated low-dose SIVmac239 challenge of AAV-immunized and control animals. (A) Kaplan-Meier analysis of the three test groups. The
percentage of animals remaining uninfected is plotted against the number of SIV exposures. SIV virus challenges were conducted in 3-week intervals. Four
low-dose challenges with one half-maximal infectious dose (1x ID50) were followed by a two ID50 (2x) and a subsequent ten ID50 (10x) challenge. The
survival curves are not significantly different (Mantel-Cox test). (B) Peak viral load comparison. The geometric mean (red line) is significantly different in the
5L7 IgG1 group compared to the control group (two-tailed, unpaired t test). (C) Set-point viral load analysis. All values within one group between weeks 8 and
25 were averaged, the resulting values were logarithmized (log10) and compared to each other. The geometric mean of the 5L7 IgG1 group differs
significantly from the other two groups (two-tailed, unpaired t test). (D) Time of peak viremia. Most of the immunized animals show peak viremia at week 3,
while 5 of 6 controls peak at week 2. (E and F) Viral loads in vivo after infectious exposure with SIVmac239. Viral loads in plasma of AAV animals (blue) and
controls (red) measured as SIV RNA genome equivalent per ml are shown as a function of time since the infectious exposure. Control animal 139–08 was a
rapid progressor and had to be sacrificed after 9 weeks due to AIDS-related symptoms. Test animal 84–05 remained uninfected after 6 SIV challenges.
doi:10.1371/journal.ppat.1005090.g002
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Discussion
Given the current availability of a spectacular array of human mAbs with potent broadly-neu-
tralizing activity against HIV-1, it has become possible to envision prevention scenarios in
which cocktails of such antibodies could be used to provide a sterilizing barrier to infection
against the vast majority of HIV-1 strains circulating in the population. However, it is not prac-
tically feasible to consider passive delivery of purified mAbs over a period of years for preven-
tion purposes. AAV vectors are ideally suited for this purpose. The only protein expressed
from AAV vectors is derived from the inserted transgene put into it. As long as the protein is
viewed as self, protein expression can continue for prolonged periods. In fact, there are already
examples where proteins delivered by AAV vector have persisted at stable levels for years
[4,8,9,37], including animal 84–05 in our study. Since muscle cells exhibit little or no turnover,
they are a preferred source for long-term delivery purposes. Little or no integration of AAV
vector DNA into host genome sequences has been observed [38–40] and AAV vectors have
proven safe when used in clinical settings to reverse hereditary absence of gene function [10–
13].
The molecularly cloned SIVmac239 is a difficult-to-neutralize strain with many of the char-
acteristics of a primary isolate. It has been extensively used as a challenge strain to gauge effi-
cacy of vaccine approaches in monkeys, and it has generally proven quite difficult to achieve
protection against [29,30,41–43]. Being a molecular clone, it avoids complications of interpre-
tation that may arise when a heterogeneous mixture of sequences in an uncloned virus stock
are used and when differences in neutralization sensitivity/resistance may exist within the mix-
ture [44,45]. The presence of AAV-delivered 5L7 mAb in our experiments significantly delayed
the time to peak viral loads and significantly lowered SIVmac239 viral loads both at peak vire-
mia and at viral load set point. The lowering of viral load set points in the 5L7 mAb group was
also significantly different from the 4L6 mAb group, lending additional support to the signifi-
cance of the protective effects. It is also likely that the lack of SIVmac239 acquisition in monkey
84–05 is also a real effect of the high concentration of 5L7 mAb in this animal. The 10x (6th)
challenge of this monkey utilized the same dose of the same stock that has been used previously
in dozens of control monkeys without a failure of infection acquisition [27–35]. The protective
effects in the 5L7 mAb group occurred in the absence of any detectable neutralizing activity of
the 5L7 mAb against the SIVmac239 molecular clone even out to 1 mg/ml. To our knowledge,
this is the first demonstration of significant protective effects of a mAb in the absence of an
ability to neutralize the challenge virus [46,47].
Recent studies have emphasized the importance of Fc-mediated effector functions in con-
tributing to the protection afforded by mAbs capable of neutralizing the SHIV used for chal-
lenge [48–52]. These studies modulated the Fc-mediated effector functions of a neutralizing
mAb up or down in order to examine the effects on protective capacity. Some vaccine studies
have also found associations of ADCC activity with protective efficacy [53–57]. Effector
Fig 3. Neutralization of SIV and binding of purified proteins in vitro. The dashed line indicates 50% RLU (relative light units) representing 50%
neutralization activity against the tested SIV strain. Lowest RLU indicates highest neutralization. Binding of purified proteins was tested by a SIVmac239
gp140 ELISA, high absorbance indicates high binding. SPF serum (specific pathogen free) from naïve animals was used as negative control, a pool of
antisera from SIV-infected animals served as positive control. (A) None of the antibodies or immunoadhesins showed neutralization against the resistant
virus strain SIVmac239 tested at 50 μg/ml. Similar results were obtained in both the SEAP and TZMbl assays. (B) Neutralization curve of SIVmac239 with
5L7 IgG1 starting at 1mg/ml. (C) All of the tested antibodies and immunoadhesins showed equivalent neutralization activity against SIVmac316 with an
average IC50 (half-maximal inhibitory concentration) of 0.002 μg/ml. (D) Animal sera from week 10 after rAAV administration (see Fig 1A) were diluted to
4 μg/ml based on previous ELISA quantitations, and tested for neutralizing activity against SIVmac316. The average IC50 measured corresponds to the IC50
of the purified proteins. (E) Animal sera of 84–05 from weeks 1 and 12 after AAV administration lacked detectable neutralizing activity against SIVmac239.
(F) Antibodies and immunoadhesins were tested for their ability to bind SIVmac239 gp140. All of the antibody constructs showed equivalent binding activity
as determined by absorbance at 450 nm.
doi:10.1371/journal.ppat.1005090.g003
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functions potentially contributing to the protective effects of the 5L7 IgG1 observed in our cur-
rent study include but are not limited to ADCC activity and complement-mediated virolysis.
Along these lines, it is fascinating that the 5L7 mAb circulating in monkey 84–05 was not only
present at extraordinarily high levels, it had extraordinarily high ADCC activity on a per μg
basis. Because of the nature of the ADCC assay that was used, it seems likely that the extraordi-
narily high ADCC activity in the serum of this one animal results from differences in post-
translational modifications of the 5L7 mAb. Decreased core fucosylation or terminal sialylation
have been shown to dramatically increase Fc-mediated ADCC activity [58–62].
One question addressed in our current studies was whether the anti-anti responses to the
immunoadhesin constructs observed in Johnson et al. [4] could be avoided by delivery of
authentic IgG. The answer is a clear no. Immune responses to the delivered IgG1 antibody
described here were readily detected in 9 of the 12 test monkeys and these appeared to limit the
levels of delivered antibody that could be achieved. This is especially true of the 4L6 group in
which the levels of delivered 4L6 IgG1 mAb dropped precipitously coincident with the appear-
ance of the anti-anti responses. In separate studies, we have observed strong antibody
responses in rhesus monkeys to AAV-delivered, rhesusized anti-HIV-1 mAbs in 24 of 24
opportunities using a ssAAV1 vector design identical to the one used for the studies described
here. This contrasts strikingly with studies in humans in which 13 sequential administrations
of 1g of anti-HIV mAb failed to elicit anti-anti responses to the three different antibodies that
were used in each of the 12 test subjects [63,64]. With our 5L7 and 4L6 experiments, it is possi-
ble that a lack of natural pairing of IgG heavy and light chains contributed to their immunoge-
nicity. With our anti-HIV experiments referred to above, it is possible that the failure to
rhesusize the variable regions contributed to their immunogenicity. Nonetheless, our results
serve as a warning signal for the potential of immunogenicity problems when AAV is used to
deliver anti-HIV mAbs in human trials.
Materials and Methods
Recombinant AAV vector constructs
Coding sequences (heavy chain, light chain or bicistronic) were designed in silico, codon-opti-
mized and gene-synthesized (Genscript). 4L6 and 5L7 immunoadhesin sequences[4] served as
a template and full-length antibodies were constructed by adding CH1 domain and CL domain
of rhesus IgG to the already known immunoadhesin sequences. 4L6 and 5L7 sequences origi-
nate from recombinant anti-SIV Fab sequences derived from the bone marrow of SIV-infected
rhesus monkeys[26]. Amino acid sequence alignments of 4L6 and 5L7 variable regions to the
most closely corresponding rhesus genomic regions are depicted in (S9 Fig). Rhesus IgG1
sequence is based on accession no. AAF14058 and AAQ57555, and rhesus IgG2 sequence is
based on AAF14060 and AAQ57567. Rhesus kappa light chain was designed using CL domain
sequence from AAD02577. Synthesized fragments were then cloned into NotI site of scAAV or
ssAAV vector plasmids[4]. Both 4L6 and 5L7 recognize gp120 and gp140 forms of the envelope
glycoprotein.
Fig 4. ADCC activity of purified proteins and sera against SIV-infected target cells in vitro. The dashed line indicates 50% RLU (relative light units) or
50% ADCC activity against SIV-infected target cells. ADCC was measured by the luciferase activity in SIV-infected cells after an 8 to 10 h incubation in the
presence of a macaque CD16+ NK cell line and a serial dilution of antibodies or animal sera. The loss of RLU indicates the loss of virus-infected cells during
the 8 to 10 h incubation period and represents a high ADCC activity. Purified 5L7 IgG1 was diluted to match the equivalent 5L7 IgG1 concentration of 5L7
IgG1-containing animal sera from week 21 post AAV administration, and compared for mediating ADCC towards (A) SIVmac239-infected cells and (B)
SIVmac316-infected cells. The ADCC activities of sera from 153–10 and 157–10 overlapped with the purified protein at their corresponding concentration.
5L7 IgG1-containing animal serum from 84–05 mediated superior ADCC activity compared to purified 5L7 IgG1 at equivalent concentration of this antibody.
doi:10.1371/journal.ppat.1005090.g004
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Rhesus IgG proteins
HEK293T cells (ATCC) were transfected with rAAV vector plasmids and proteins were puri-
fied from cell culture supernatant using Protein A Plus (Pierce). Concentration of purified pro-
teins was determined by NanoDrop (Thermo Scientific) A280 measurement and purity and
integrity was verified by Coomassie staining (Life Technologies).
Binding assay
Immunoadhesins and mAbs were tested for their ability to bind SIVmac239 envelope glyco-
protein by ELISA. Test plates were coated with recombinant gp140 of SIVmac239 (Immune
Technology) for 1 h at 37°C. Plates were washed using PBS-Tween20 (Sigma-Aldrich) and sub-
sequently blocked with 5% nonfat dry milk in PBS (Bio-Rad). Immunoadhesins, mAbs, posi-
tive and negative sera from macaques were serially diluted 1:3 in blocking buffer and added to
the test plate. After 1 h of incubation at 37°C the plates were washed again and a HRP-conju-
gated goat anti-rhesus IgG H+L (SouthernBiotech) was then added for detection. The reaction
was stopped after 1 h at 37°C and plates were washed 10 times. Subsequently, TMB substrate
and stop solutions (SouthernBiotech) were added and Absorbance at 450 nm was measured in
a microplate reader (PerkinElmer).
Virus neutralization assay
Neutralization activity of mAbs against tested SIV strains was measured by either a luciferase-
based assay as described previously (TZMbl)[36] or an assay that is based on secreted alkaline
phosphatase (SEAP)[36]. Virus and a serial dilution of Abs or serum were incubated for 1 h at
37°C before adding it to the TZMbl or SEAP cells (ATCC). Neutralization was assessed two
days later by measuring luminescence in a 96-well plate reader (Perkin Elmer).
ADCC assay
Measurement of antibody effector function was performed by NK cell activity towards virus-
infected target cells expressing luciferase[36]. A CD4+, CCR5+ T-cell line was infected with
SIV four days prior assay readout. These target cells were washed three times on the day of the
assay and co-cultured with a NK cell line expressing rhesus CD16 and a serial dilution of mAb
or heat-inactivated serum for 8 to 10 hours. Cells were lysed afterwards and ADCC was mea-
sured as the loss of luciferase activity in the cell culture supernatant.
Recombinant AAV
Production of rAAV was conducted as described previously[65]. In short, HEK 293 cells were
transfected with rAAV vector plasmid and two helper plasmids to allow generation of infec-
tious AAV particles. After harvesting transfected cells and cell culture supernatant, rAAV was
purified by three sequential CsCl centrifugation steps. Vector genome number was assessed by
Real-Time PCR, and the purity of the preparation was verified by electron microscopy and sil-
ver-stained SDS-PAGE.
Animals and AAV immunization
The animals in our study were rhesus macaques of Indian-origin (Macaca mulatta). We pur-
chased the 18 monkeys and housed them at the New England Primate Research Center of Har-
vard Medical School in a biocontainment facility in accordance with standards of the
Association for Assessment and Accreditation of Laboratory Animal Care and the Harvard
Medical School Animal Care and Use Committee. The animal samples used here were collected
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under experimental protocols approved by the Harvard Medical Area Standing Committee on
Animals, and conducted in accordance to the Guide for the Care and Use of Laboratory Ani-
mals. All macaques were tested negative for the presence of antibodies to SIV and AAV1 capsid
prior AAV administration. The weights of the animals ranged from 2.5 kg to 17.2 kg at the
time of immunization. The six 5L7 IgG1 animals were split in two groups and each animal
received a total of 1.6 x 1013 AAV vector genomes. One group received 1.6 x 1013 particles of
ssAAV expressing the heavy and light chains of 5L7 IgG1, the other group received 0.8 x 1013
particles of scAAV expressing the heavy chain of 5L7 IgG1 plus 0.8 x 1013 particles of the
scAAV expressing the kappa light chain of 5L7 IgG1. AAV administration was conducted by
four equal and deep intramuscular injections, where each animal received two separate 0.5 ml
injections into both quadriceps. All 6 animals that received 4L6 IgG1 were given a total of 2.5 x
1013 AAV vector genomes per monkey.
Ethics statement
The animal management program of Harvard Medical School is accredited by the American
Association for the Accreditation of Laboratory Animal Care, and meets National Institutes of
Health standards as set forth in the Guide for the Care and Use of Laboratory Animals (DHHS
Publication No. (NIH)85-23 Revised 1985). The Institute also accepts as mandatory the PHS
Policy on Humane Care and Use of Laboratory Animals by Awardee Institutions and NIH Prin-
ciples for the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Train-
ing. There is on file with the Office for Protection from Research Risks an approved Assurance
of Compliance.
Animal facilities were administrated by the state and met Harvard standards for humane
care and use of animals through a program of veterinary care, inspection and oversight. Animal
care and welfare is the charge of the Committee on Animals, appointed by the Dean, consisting
of 22 members comprising 4 veterinarians, 2 public representatives, and 16 doctoral level rep-
resentatives of principal sites of animal use by Harvard Faculty. Additionally, local facilities are
guided and monitored in daily activities by 8 departmental animal use committees. The proce-
dure to avoid unnecessary discomfort, pain, or injury to animals are those prescribed in the
aforementioned NIH “Guide” and additional detailed protocols for anesthesia, analgesia, tran-
quilization, euthanasia, or restraint have been developed and circulated by the Committee on
Animals.
Rhesus macaques on study were housed in the biocontainment facility of the New England
Primate Research Center of Harvard Medical School under approved protocol 04655 of the
Institutional Animal Care and Use Committee (IACUC) of Harvard Medical School. The Har-
vard Office of Microbiological Safety oversaw the design and construction of this facility. It
includes individual Hepa-filtered caging for monkeys and additional features such as a pass-
through autoclave, footpedal-operated sink, and a special safety cabinet for surgical and nec-
ropsy procedures. The facility has restricted access. Individuals entering the room must suit-up
with disposable cap, mask, coverall, gloves and shoe covers. Procedures used in the care and
feeding of these animals are posted on the entry door. The animals were provided ad lib access
to municipal source water, offered commercial monkey chow twice daily, and offered fresh
produce a minimum of three times weekly. Light cycle was controlled at 12/12 hours daily.
Containment facilities and procedures for macaques experimentally infected with RRV and
SIV have been reviewed and approved by the Harvard Committee on Microbiological Safety.
Animals housed in the biocontainment facilities received a daily health check by both ani-
mal care technicians and veterinary professional staff. All animals received a complete physical
examination on the average of once every four to six weeks. A comprehensive environmental
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enrichment and psychological well-being plan was in place for primates in the described stud-
ies and is available for inspection by the United States Animal and Plant Health Inspection Ser-
vice (APHIS) and to officials of any pertinent organization. Euthanasia took place at defined
experimental endpoints using protocols consistent with the American Veterinary Medical
Association (AVMA) guidelines. Animals were first sedated with intramuscular ketamine
hydrochloride at 20 mg/kg body followed by sodium pentobarbital (100 mg/kg) intrave-
nously to achieve euthanasia.
Serum concentration of AAV-delivered mAb
To measure the concentration of 5L7 IgG1 and 4L6 IgG1 in vivo we performed a SIVmac239
gp140 (Immune Tech)/anti-rhesus IgG ELISA (Southern Biotech). Absorbance at 450 nm was
compared to a serial dilution of purified mAb produced in HEK 293T cells, and the amount of
antibody in serum was extrapolated based on the mAb standard curve. Reference protein was
quantified by NanoDrop (Thermo Scientific) A280 measurement and purity was verified by
Coomassie staining (Life Technologies). Levels of AAV-delivered antibody were measured up
to the time of SIV challenge: 44 weeks (5L7 IgG1) and 14 weeks (4L6 IgG1) after AAV adminis-
tration. The appearance of anti-env antibody responses following SIV infection obviated our
ability to measure levels of delivered mAb at post-infection time points.
Anti-anti response
Humoral responses to the AAV-delivered mAb were measured by an antibody capture ELISA.
Plates were coated with purified 5L7 IgG1 and 4L6 IgG1. After coating and blocking, we incu-
bated the plates with antisera from the AAV-immunized monkeys. For detection, we probed
with a HRP-conjugated anti-human lambda light chain antibody (Southern Biotech). This sec-
ondary antibody did not cross-react with the coated mAb on the plates since 5L7 IgG1 and 4L6
IgG1 harbor a kappa light chain. For detecting kappa anti-anti responses we produced recom-
binant versions of mAb that harbor a lambda light chain and detected kappa chain anti-mAb
antibodies by probing with a HRP-conjugated anti-human kappa light chain antibody (South-
ern Biotech). To assess the target of the anti-anti response we tested the reactivity of antisera
against AAV-delivered mAb and its immunoadhesin version as well as against antibody or
immunoadhesin that was not given to one group of animals. For example, reactivity of antisera
from 5L7 IgG1 recipient was tested against purified 5L7 IgG1, 5L7 immunoadhesin, 4L6 IgG1
and 4L6 immunoadhesin.
SIVmac239 challenge and viral load measurement
Infectious SIVmac239 was produced in PBMCs as described previously [27]. SIV challenges
were conducted by repeated low dose intravenous injection with SIVmac239. The challenge
dose was 1x AID50 for the first four injection and was elevated to 2x AID50 and 10x AID50 for
the fifth and sixth challenge, respectively. The animals were exposed to SIV every three weeks
or until positive viremia was measured. Challenge virus in plasma was detected by quantitative
real-time RT-PCR using primers specific for SIV gag as described previously[66].
Reactivity of serum to gp41
Presence or absence of anti-SIV envelope antibodies following SIV challenge was assessed by
measuring the reactivity of sera (before and after challenge) against purified SIVmac251 trun-
cated gp41 protein (ImmunoDX) by ELISA.
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Supporting Information
S1 Fig. Schematic illustration of vector design and biosynthesis of full-length antibodies.
Two strategies are used to generate authentic IgGs delivered by recombinant adeno-associated
virus. (Top) In the two vector approach heavy (H) and light (L) chains of immunoglobulins
are expressed from separate self-complementary adeno-associated virus vectors (scAAV). The
expression cassettes consisting of a short CMV enhancer/CMV promoter, SV40 intron, rhesus
macaque immunoglobulin G (IgG) heavy chain or light chain coding sequences (CDS) and
polyA signal are flanked by AAV serotype 2 inverted terminal repeats (ITR). The 3' ITR of the
scAAV vector has the wild-type (wt) sequence, whereas the 5' ITR is mutated lacking the wild-
type terminal resolution site (trs). Heavy and light chains are individually transcribed and sub-
sequently translated into the lumen of the endoplasmic reticulum (ER) where they co-transla-
tionally fold, undergo N-glycosylation and finally assemble. After further modifications in the
Golgi apparatus authentic IgGs are secreted. (Bottom) To ensure delivery of heavy and light
chains into the cells at equimolar levels, both polypeptides are expressed from one open read-
ing frame using a F2A self-processing peptide from foot-and-mouth disease virus. The bicistro-
nic single-stranded adeno-associated virus (ssAAV) construct consists of CMV promoter,
SV40 intron, heavy and light chain coding sequences (CDS), separated by F2A, SGSG, Furin
peptide and polyA signal flanked by AAV2 wt ITRs. In the one vector approach both heavy
and light chain are transcribed from a single mRNA sequence that is subsequently translated
into the ER lumen. While being elongated, the polyprotein sequence undergoes self-cleavage
through a ribosomal 'skip' mechanism when reaching amino acid residues of F2A. Then, the
two polypeptide chains are folded, glycosylated and assemble within the lumen of the ER. Fur-
ther modifications in the Golgi lead to removal of F2A peptide residues induced by Furin cleav-
age. Carboxypeptidases then remove redundant Furin residues. Full-length, authentic IgGs are
finally secreted.
(TIF)
S2 Fig. Overlay of lambda and kappa responses to 5L7 IgG1 with levels of 5L7 IgG1 in
serum. Concentration of 5L7 IgG1 expressed in μg/ml (in black) was overlaid with lambda
anti-5L7 responses (in red) and kappa anti-5L7 (in blue), both expressed as absorbance at
450 nm in an ELISA. Each individual panel represents one monkey from the 5L7 mAb group.
(TIF)
S3 Fig. Overlay of lambda and kappa responses to 4L6 IgG1 with levels of 4L6 IgG1 in
serum. Concentration of 4L6 IgG1 expressed in μg/ml (in black) was overlaid with lambda
anti-4L6 responses (in red) and kappa anti-4L6 (in blue), both expressed as absorbance at
450 nm in an ELISA. Each individual panel represents one monkey from the 4L6 mAb group.
(TIF)
S4 Fig. Reactivity of serum against SIV gp41. Pre-challenge sera (in blue bars) and sera
11 weeks post-infectious exposure (9 weeks after 10x challenge for 84–05; in red bars) were
tested by ELISA against SIV gp41 recombinant protein.
(TIF)
S5 Fig. Analysis of peak viremia and mAb levels in the 5L7 mAb group. A Pearson’s correla-
tion test was conducted for the average levels of 5L7 IgG1 in serum (weeks 10–44) and viral
loads at peak height. The respective animal identification numbers are included in the graph.
Animal 84–05 was excluded since it remained uninfected. Animals with the lowest levels of
5L7 mAb had the highest peak viral loads; the results were not statistically significant
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(P = 0.0658).
(TIF)
S6 Fig. Comparison of 4L6 mAb levels to the time of peak viremia. Levels of 4L6 IgG1 in
serum were measured on the day of infectious exposure and compared to the time of peak vire-
mia in the 4L6 mAb group. Animal identification numbers are included in the graph with their
respective effective infectious SIV exposure. Animals that displayed SIV peak viremia at week 3
had no significantly higher levels of 4L6 IgG1 at the time of infectious exposure (P = 0.4433).
(TIF)
S7 Fig. Lack of ADCC-enhancing activity in pre-AAV serum from 84–05. Pre-AAV serum
(week -1) from animal 84–05 was tested for potential ADCC activity against SIVmac239
infected target cells. Test sera were compared to ADCC of purified 5L7 IgG1 produced in 293T
cells (84.2 μg/ml corresponds to the serum conc. of 5L7 IgG1 at week 21 post AAV administra-
tion). Purified 5L7 IgG1 was added to the pre-AAV serum from 84–05 and included in this
assay. Pre-AAV serum not only had no detectable ADCC activity, it did not have any ADCC-
enhancing activity when added to purified 5L7 IgG1.
(TIF)
S8 Fig. ADCC activity of week 24 sera and purified 5L7 IgG1 against SIVmac239-infected
target cells. ADCC was measured by the luciferase activity in SIV-infected cells after a 10 h
incubation in the presence of a macaque CD16+ NK cell line and a serial dilution of antibodies
or animal sera. The loss of RLU indicates the loss of virus-infected cells during the 10 h incuba-
tion period and represents a high ADCC activity. Purified 5L7 IgG1 was diluted to match the
equivalent 5L7 IgG1 concentration of 5L7 IgG1-containing animal sera from week 24 post
AAV administration, and compared for mediating ADCC towards SIV-infected target cells.
Each monkey is plotted separately (serum and corresponding mAb), while the same control
sera is used in each individual panel for comparison.
(TIF)
S9 Fig. Amino acid sequence alignments of 4L6 and 5L7 variable regions to the most closely
corresponding rhesus genomic regions. Variable regions of heavy chain (VH) and light chain
(VL, kappa) of the mAbs 4L6 and 5L7 were compared to the rhesus monkey immunoglobulin
germline sequences using the IMGT/V-QUEST and IMGT/BLAST analysis tools (available
through http://www.imgt.org). Comparison of variable regions was conducted based on
sequence identity with the V-gene repertoire (IGHV and IGKV) of Macaca mulatta; CDR3 and
adjacent FR4 germline sequences were not depicted at full-length since the complete segments
of those sequences are created from recombination with D-genes and J-genes. Identical amino
acids are shaded in grey, framework regions (FR) and hypervariable complementarity-deter-
mining regions (CDR) are indicated by colored arrows. Corresponding V-genes and alleles
were selected based on highest sequence identity with the 4L6 and 5L7 variable regions.
(TIF)
S1 Table. Details on monkeys used in the study.
(TIF)
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